Point-of-care testing performed by healthcare professionals outside the hospital setting : consensus based recommendations from the IFCC Committee on Point-of-Care Testing (IFCC C-POCT)
© 2023 Walter de Gruyter GmbH, Berlin/Boston..
The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Point-of-Care Testing (C-POCT) supports the use of point-of-care testing (POCT) outside of the hospital setting performed by healthcare professionals without formal laboratory education because of its numerous benefits. However, these benefits are associated with risks that must be managed, to ensure the provision of reliable test results and minimize harm to the patient. Healthcare professionals, local regulatory bodies, accredited laboratories as well as manufacturers should actively be engaged in education, oversight and advice to ensure that the healthcare professional selects the appropriate equipment and is able to analyze, troubleshoot and correctly interpret the point-of-care (POC) test results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 61(2023), 9 vom: 28. Aug., Seite 1572-1579 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khan, Adil I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Audit |
|---|
| Anmerkungen: |
Date Completed 17.07.2023 Date Revised 24.01.2024 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2023-0502 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357695186 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357695186 | ||
| 003 | DE-627 | ||
| 005 | 20240125231843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2023-0502 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1270.xml |
| 035 | |a (DE-627)NLM357695186 | ||
| 035 | |a (NLM)37267483 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khan, Adil I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Point-of-care testing performed by healthcare professionals outside the hospital setting |b consensus based recommendations from the IFCC Committee on Point-of-Care Testing (IFCC C-POCT) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.07.2023 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Walter de Gruyter GmbH, Berlin/Boston. | ||
| 520 | |a The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Point-of-Care Testing (C-POCT) supports the use of point-of-care testing (POCT) outside of the hospital setting performed by healthcare professionals without formal laboratory education because of its numerous benefits. However, these benefits are associated with risks that must be managed, to ensure the provision of reliable test results and minimize harm to the patient. Healthcare professionals, local regulatory bodies, accredited laboratories as well as manufacturers should actively be engaged in education, oversight and advice to ensure that the healthcare professional selects the appropriate equipment and is able to analyze, troubleshoot and correctly interpret the point-of-care (POC) test results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a audit | |
| 650 | 4 | |a competency | |
| 650 | 4 | |a instrument correlation | |
| 650 | 4 | |a point-of-care testing (POCT) | |
| 650 | 4 | |a training | |
| 700 | 1 | |a Pratumvinit, Busadee |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobs, Ellis |e verfasserin |4 aut | |
| 700 | 1 | |a Kost, Gerald J |e verfasserin |4 aut | |
| 700 | 1 | |a Kary, Heba |e verfasserin |4 aut | |
| 700 | 1 | |a Balla, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Shaw, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Milevoj Kopcinovic, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Vaubourdolle, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Oliver, Paloma |e verfasserin |4 aut | |
| 700 | 1 | |a Jarvis, Paul R E |e verfasserin |4 aut | |
| 700 | 1 | |a Pamidi, Prasad |e verfasserin |4 aut | |
| 700 | 1 | |a Erasmus, Rajiv T |e verfasserin |4 aut | |
| 700 | 1 | |a O'Kelly, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Musaad, Samarina |e verfasserin |4 aut | |
| 700 | 1 | |a Sandberg, Sverre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 61(2023), 9 vom: 28. Aug., Seite 1572-1579 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:9 |g day:28 |g month:08 |g pages:1572-1579 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2023-0502 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 9 |b 28 |c 08 |h 1572-1579 | ||